Objective: To determine expression of the P2X 7 receptor in normal and in cancer uterine tissues. The rationale was that the receptor P2X 7 regulates constitutive apoptosis in uterine epithelial cells, and previous studies showed diminished P2X 7 -mediated apoptosis in cancer uterine cells compared with normal cells. Methods: A clinical, experimental feasibility study. Normal (n = 42) and cancer uterine tissues (n = 47) were obtained from a total of 72 women ages 25 to 75. End points for P2X 7 mRNA were quantitative PCR and in situ hybridization, and end points for P2X 7 protein were Western blots and immunostaining using anti-P2X 7 antibody. Results: (a) In normal uteri, P2X 7 mRNA and protein were expressed predominantly in the epithelial (endometrial, endocervical, and ectocervical) cells. (b) Expression of the P2X 7 mRNA and protein was absent from endometrial and endocervical adenocarcinoma tissues and from cervical squamous cell carcinoma tissues. (c) In cervical dysplasia, P2X 7 protein was absent in the dysplastic lesions. (d) Semiquantitative analysis using P2X 7 mRNA (normalized in each tissue to the constitutive glyceraldehyde-3-phosphate dehydrogenase) and P2X 7 protein levels (normalized in each tissue to the constitutive tubulin) revealed that P2X 7 mRNA and/or protein levels can distinguish uterine normal from cancer tissues at high degrees of sensitivity (92%, 100%) and specificity (100%, 90%). Summary and Conclusions: (a) Levels of the P2X 7 are lower in uterine epithelial cancer tissues than in the corresponding normal tissues. (b) The data suggest that tissue P2X 7 mRNA and protein levels could be used as a novel biomarker to differentiate normal and cancer uterine epithelial tissues. (Cancer Epidemiol Biomarkers Prev 2006;15(10):1906 -13) 
Introduction
The receptor P2X 7 belongs to the P2X subfamily of P2 nucleotide receptors (1, 2) , which are membrane-bound, ligand-operated channels (3) (4) (5) . ATP is the naturally occurring ligand for the P2X 7 , and activation of the receptor by extracellular ATP stimulates several responses, including formation of pores in the plasma membrane that allow passage of cations up to 900 Da through the pores (6) . In human cervical epithelial cells, Ca 2+ influx via P2X 7 pores mediates apoptosis constitutively by an autocrine-paracrine mechanism (7) . Thus, ATP secreted by cells into the extracellular space reaches high nanomolar to low micromolar concentrations, which suffice to activate the P2X 7 receptor (7, 8) , and cells expressing the functional receptor are targeted to the proapoptotic effect of ATP (9) .
Human uterine epithelial cells express two P2X 7 isoforms: the full-length 85-65 kDa P2X 7 receptor (P2X 7 ; ref. 10 ) and an inactive 42 to 45 -kDa truncated variant (P2X 7-j ) that lacks the entire intracellular COOH terminus, the second transmembrane domain, and the distal third of the extracellular loop of the P2X 7 (9) . The P2X 7-j variant is deficient in ligand binding, pore formation, and mediation of apoptosis; however, it can interact and hetero-oligomerize with the full-length P2X 7 (9) . Because P2X 7 receptor functions depend on oligomerization of P2X 7 molecules into homotrimers (11) , any interaction between the P2X 7-j and the full-length P2X 7 can block P2X 7 mediated channel activity, pore formation, and induction of apoptosis (9) .
Earlier studies showed that baseline and ligand-induced P2X 7 -mediated apoptosis is greater in normal human ectocervical epithelial cells than in cancer human cervical cells (7) . More recent results showed that normal and cancer human cervical cells express the variant P2X 7-j but normal cells express higher levels of the full-length P2X 7 than cancer cells (9) . These data provide a possible mechanistic explanation for the finding of lesser degree of P2X 7 -mediated apoptosis in cancer cervical cells. Accordingly, normal cells expressing predominantly the P2X 7 isoform are more likely to form active [(P2X 7 )3] homotrimers, whereas cancer cells expressing low levels of the P2X 7 isoform are more likely to form inactive heterotrimers, such as the [(P2X 7 )2]/[(P2X 7-j )] or the [(P2X 7 ) ]/ [(P2X 7-j )2] or the inactive [(P2X 7-j )3] homotrimers (9) .
The objective of the present study was to better understand the clinical significance of P2X 7 receptor expression in vivo in normal and cancer human uterine tissues. Using semiquantitative analyses, we show that levels of P2X 7 receptor mRNA and protein in tissues obtained from women with ectocervical, endocervical, and endometrial cancers are significantly lower than from the corresponding normal tissues. The results suggest that tissue levels of the P2X 7 receptor can serve as a novel biomarker to detect uterine cancers in women.
Materials and Methods
Human Tissues and Cell Cultures. Discarded human uterine tissues from women undergoing hysterectomy for indications unrelated to the present study were obtained according to Institutional Review Board protocols 12-03-50 and 03-90-300 from the Human Tissue Procurement Facility of Tissues were collected over a period of 6 months based on availability. Some of the tissues were used for assay development and pilot experiments. The secondary intention of the study was to determine the size effect if differences among groups (normal versus cancers) were found and to conduct a feasibility comparative study. The data presented in this article are considered preliminary, and no formal power analysis was done to determine the number of tissues to be included in the comparative part of the study.
On removal, uterine specimens were delivered to the Department of Pathology at University Hospitals of Cleveland or at the Ohio State University where the bulk of the tissue was used to establish the histologic diagnosis. Tissues selected by the pathologists for the purpose of the present study were snap frozen in liquid nitrogen, shipped on dry ice, and stored at À80jC until assayed. Some tissues were fixated and embedded in paraffin according to standard procedures. Tissue processing for RNA and protein assays was described (9) .
Tissues were obtained from a total of 72 women ages 25 to 75. The study used histologically normal 15 endometrial, 3 endocervical, and 24 ectocervical tissues and 29 endometrial cancers (28 endometrioid adenocarcinomas and 1 mixed adenomatous-mullerian cancer), 6 endocervical cancers (all adenocarcinomas), and 10 ectocervical cancers (all squamous cell carcinomas). Normal plus cancer tissues were retrieved from uterine specimens of 15 women: 10 endometrial, 3 endocervical, and 2 ectocervical. The histologic diagnoses presented below were assigned by the Departments of Pathology at University Hospitals of Cleveland or at the Ohio State University.
Cell culture techniques of normal human keratinocytes and the transformed cervical cancer cell line CaSki (12, 13) and the method of doxycyline-inducible expression of P2X 7 or P2X 7-j in Madin-Darby canine kidney cells were described (9) .
Quantitative Real-time PCR. Quantitative PCR assays, including specific primers and conditions for amplification of the human full-length P2X 7 gene (Genbank Y09561), the truncated variant P2X 7-j (Genbank DQ399293), as well as the constitutive glyceraldehyde-3-phosphate dehydrogenase, were described (9) . Quantitative PCR results were calculated using the comparative threshold cycle (C t ) method of relative quantitation. Verification of reverse transcription was done by sequencing the PCR products using the above antisense primers. For the full-length P2X 7 fragment, the conjunction sequences of exon 8 (bold letters) and exon 9 (italics) were confirmed as follows: CCTTGTACCCTGGCTACAACTT-CAGATACGCCAAGTACTACAAGGAAA! (856 bp). For the truncated P2X 7-j fragment, the conjunction sequences of exon 7 (bold letters) and exon 9 (italics) were confirmed as follows: TTCAGATGTGGCAATTCAGATACGCCAAGTACTACAAG-GGAAA! (726 bp). P2X 7 RNA In situ Hybridization. Primers for the sense probe of the full-length P2X 7 cDNA template (synthesized by Invitrogen, Carlsbad, CA) were (T7)-5 ¶-TGTAATACGACT-CACTATAGGGCAATTCAGGGCGGAATAATGGGCAT and 3 ¶-AGGGTACAAGGACACGTTGG, and for the antisense probe, 5 ¶-CAATTCAGGGCGGAATAATG and (T7)-3 ¶-TGTAATACGACTCACTATAGGGTAGCCAGGGTACAAG-GACACGTTGG. The probes were synthesized by using 100 ng PCR fragments plus 2 AL DIG labeling mix (Roche, Indianapolis, IN), 2 AL transcription buffer, 40 units of T7 polymerase (Roche), and H 2 O in a total volume of 20 AL. The mixture was incubated at 37jC overnight, and the reaction was stopped by adding 0.8 AL of 0.5 mol/L EDTA. For ethanol precipitation, 2.5 AL of 4 mol/L lithium chloride plus 75 AL prechilled (À20jC) ethanol were added to the mixture followed by incubation at À80jC for 2 hours and recentrifugation at 13,000 Â g for 5 minutes at 4jC. The pellet was dried, dissolved in 50 AL diethyl pyrocarbonate water, and stored at À80jC.
Tissue slices on slides were deparaffinized, rehydrated, and postfixed with 4% paraformaldehyde. After treatment with 0.04 N HCl for 20 minutes at room temperature, tissues were digested with 20 Ag/mL proteinase K for 20 minutes at 37jC. Cultured cells were plated on polylysine-coated coverslips and grown in culture medium to subconfluence. After fixation with 4% paraformaldehyde/PBS for 15 minutes at room temperature, cells were washed with PBS containing 0.1% active diethyl pyrocarbonate. The cells were permeabilized with 0.1% Triton X-100/PBS/diethyl pyrocarbonate for 5 minutes and equilibrate with 5Â SSC/diethyl pyrocarbonate for 15 minutes. Specimens (tissues or cells) were prehybridized for 2 hours at 58jC in hybridization mix containing 5Â SSC/50% formamide/40 Ag/mL salmon sperm DNA and hybridized at 58jC overnight with 150 ng/AL sense or antisense probes for the full-length P2X 7 in hybridization mix solution. Following the incubation, specimens were washed in 2Â SSC for 15 minutes at room temperature, then in the same buffer for 50 minutes at 65jC, and in 0.1Â SSC for 1 hour at 65jC and equilibrated with TN buffer containing 100 mmol/L Tris and 150 mmol/L NaCl (pH 7.5). Specimens were incubated with alkaline phosphatase -conjugated anti-digoxigenin antibody (1:1,000; Roche) in blocking solution for 2 hours at room temperature. Excess antibody was removed by two 15-minute washes in washing buffer and once by washing with detection buffer (Roche). Color development was done at room temperature in BM Purple alkaline phosphatase substrate (Roche) for 20 minutes in the dark, and staining was stopped with detection buffer. For cell cultures, nuclei were counterstained with methyl green or fast red and slides were dried with ethanol and mounted with VectaMount (Vector Laboratories, Burlingame, CA). Straining was evaluated using Nikon Eclipse 80i microscope (Nikon, Melville, NY).
Protein Methods. Western blots were done as described (14) . Aliquots of postnuclear supernatants of cell lysates were normalized to 15 Ag protein, separated in SDS-PAGE, and blotted by Western analysis. The methods of immunostaining and densitometry were described (14) . P2X 7 receptor polypeptides (P2X 7 and P2X 7-j ) were visualized using rabbit polyclonal anti-P2X 7 receptor (in the absence or presence of its antigen peptide; Alomone Laboratories, Jerusalem, Israel; refs. 10, 14) . The anti-tubulin and anti-E-cadherin antibodies as well as secondary antibodies were described (10, (14) (15) (16) .
All chemicals, unless specified otherwise, were obtained from Sigma Chemical (St. Louis, MO). Data were tabulated in contingency tables, and significance of differences between groups was estimated by m 2 test.
Results
P2X 7 and P2X 7-j Expression. P2X 7 expression in normal and cancer endometrial and cervical tissues was determined in terms of immunoreactivities with the anti-P2X 7 antibody that could be blocked by coincubation with the P2X 7 antigen. Results of Western blots are shown in Fig. 1A [lanes 1 and 3 (CaSki) and lanes 2 and 4 (patient 120)] and confirm (9, 10, 14) the expression of specific P2X 7 immunoreactivities of the fulllength P2X 7 (65-85 kDa) and of the truncated P2X 7-j isoform (42-45 kDa; endometrial and ectocervical tissues ( Fig. 1A and C) . However, the protein and mRNA levels of the full-length P2X 7 were significantly higher in the normal than in the cancer tissues ( Fig. 1A and C) .
P2X 7 Protein Expression
Normal Tissues. In normal uteri, P2X 7 immunoreactivity was localized predominantly in the endometrial, endocervical, and ectocervical epithelia as correlated and confirmed by costaining with the epithelial marker E-cadherin (Fig. 2, a-f , o-r, and w-zh). In all three types of epithelia, the P2X 7 staining was observed both in the membrane and in the cytoplasm of the epithelial cells (Fig. 2, c, q, and zg) . In the endometrium and endocervix, the P2X 7 antibody stained the endometrial glands (Fig. 2, a-f ) and the endocervical crypts (Fig. 2 , o-r and w-z), respectively. P2X 7 staining was uniform, both in endometrial tissues of women ages <50 (Fig. 2, a-d ) and in women ages >51 (e.g., Fig. 2 , e and f; age 67) and in endocervical tissues of women ages <50 (Fig. 2 , o-r and w-z) and in women ages >51 (data not shown).
In normal uteri, strong P2X 7 staining was found at the transition zones of the columnar-endocervical and ectocervical-squamometaplastic epithelia (Fig. 2, y and z) and of the ectocervical squamometaplastic-squamous epithelia (Fig. 2,  za and zb) .
In the normal ectocervix, P2X 7 staining was found predominantly in the epithelium, although some staining was also found in subepithelial tissues (Fig. 2, wzb) . In the ectocervical epithelium, P2X 7 staining was most abundant in the germinative (basal and parabasal) layers, both in tissues of women ages <50 (Fig. 2, zc-zf) and in women ages >51 (e.g., Fig. 2, zg and zh). P2X 7 expression was diminished in suprabasal layers of the epithelium (Fig. 2 , zc-zf), but enhanced expression was seen again in superficial layers (Fig. 2, zc-zf) , probably the result of trapped receptor in the superficial compact cells [cornified envelops (17) ; Fig. 2 , ze]. The latter statement is supported by results of in situ hybridization experiments where P2X 7 mRNA was found predominantly in the germinative layers of the ectocervical epithelium (Fig. 3, t and u) .
Uterine Cancers. Endometrial (Fig. 2, g-n) , endocervical (Fig. 2 , s-v), and ectocervical cancers (Fig. 2 , zs-zv) lacked P2X 7 staining. The endogenous positive controls were sections comprising endometrial cancers plus normal glands in the same slice (Fig. 2, k-n) . In those cases, the anti-P2X 7 antibody stained positively the normal glands but did not stain the cancer tissues (Fig. 2, k and m) .
Interesting results were obtained in tissues from women with ectocervical dysplasia. Analysis of tissues with different grades of ectocervical dysplasia showed that the dysplastic lesions per se lacked P2X 7 staining (Fig. 2, zi-zr) . In addition, when the cross-section was evaluated in its entirety, there was gradual decrease in staining as the degree of abnormality progressed. Thus, in mild dysplasia, about one third of the epithelium in the basal side lacked P2X 7 staining (Fig. 2, zi-zl) . In moderate dysplasia, about one half of the epithelium extending from the basal side lacked P2X 7 staining (Fig. 2 , zm-zp), and pockets lacking staining could be seen projecting more superficially (Fig. 2, zm and zo) . This was in contrast to the rather uniform graded staining in normal ectocervical epithelium (Fig. 2, zc) . In severe dysplasia, about two thirds of 3 and 4) of the P2X 7 antigen. Numbers at the top of the figures, patients' coded identifiers. Case 120 was normal endometrium. In cases 216, 164, and 460, endometrial normal (N) and cancer (C) tissues were obtained from the same woman. Where indicated, gels were reprobed with anti-tubulin antibody. Coincubation of the anti-P2X 7 antibody with the P2X 7 antigen blocked expression of the 65 to 85 -kDa (P2X 7 ) and the 42 to 45-kDa (P2X 7-j ) immunoreactivities. B. Immunostaining of normal endometrium with anti-P2X 7 antibody in the presence or absence of the P2X 7 antigen. The experiment was repeated thrice with similar trends. C. P2X 7 (black columns) and P2X 7-j (white columns) mRNA assayed by real-time reverse transcription-PCR using normal and cancer endometrial tissues obtained from women with the designated codes.
the epithelium extending from the basal side lacked P2X 7 staining, and staining was observed only in the most superficial layer composed of superficial cells and envelops (Fig. 2, zq and zr) . Some cases of severe dysplasia lacked P2X 7 staining entirely (data not shown), similar to cases of cervical squamous cell carcinoma (i.e., Fig. 2, zs and zu) .
Collectively, the data in Fig. 2 indicate that (a) the P2X 7 is expressed predominantly in the epithelial components of the uterus, (b) uterine epithelial cancerous lesions lack expression of the P2X 7 , and (c) in ectocervical dysplasia the dysplastic cells lacked P2X 7 staining and the total P2X 7 staining across the epithelium correlated reciprocally with the severity of the dysplasia.
P2X 7 mRNA Expression: In situ Hybridization. The technique of in situ hybridization was used to determine the cellular distribution of P2X 7 mRNA in normal and cancer uterine tissues. The experiments focused on the expression of the full-length P2X 7 using a cDNA template (probe) designed to hybridize specifically with the full-length P2X 7 . The sensitivity of the method was tested using human keratinocytes, which express endogenously the full-length P2X 7 . In preparations of cells not exposed to the probe (Fig. 3A) or in preparations of cells hybridized with the sense P2X 7 probe (Fig. 3B) , no staining was obtained with the anti-digoxigenin antibody. In contrast, hybridization with the antisense P2X 7 probe elicited significant perinuclear and cytoplasmic staining (Fig. 3C) .
The specificity of the P2X 7 probe to distinguish P2X 7 and P2X 7-j mRNA in situ was tested using Madin-Darby canine kidney cells that lack endogenous expression of the receptor. Madin-Darby canine kidney cells expressing tetracycline repressor regulating system (to prevent potential toxic effects of the interest genes) were transfected with either the P2X 7 or P2X 7-j cDNAs. Cells were grown in the presence or absence of doxycyline [to induce expression of the P2X 7 or P2X 7-j proteins (9)], and cell preparations were hybridized either with the sense or with the antisense P2X 7 probe. The results in Fig. 3  (d-k) show that specific hybridization of the P2X 7 probe was seen only in doxycyline-treated cells transfected with the P2X 7 cDNA and hybridized with the antisense P2X 7 probe (Fig. 3, g) . Collectively, the results in Fig. 3 (a-k) validate the usefulness of the P2X 7 cDNA template for detection of the full-length P2X 7 mRNA using the in situ hybridization technique.
In cross-sections of human normal uterine tissues, specific intense perinuclear and cytoplasmic P2X 7 mRNA staining decorated the epithelial components of the endometrial glands (Fig. 3, i and m) , the endocervical crypts (Fig. 3, p and q) , and Figure 2 . Immunostaining of endometrial (a-n), endocervical (o-z), and ectocervical (w-zv ) normal (a-f, o-r, and w-zh ), dysplasia (zi-zr), and cancer tissues [endometrial (g-n) and endocervical (s-v) adenocarcinomas and squamous cell carcinoma (zs-zv)] with the anti-P2X 7 antibody (a, c, e, g, i, k, m, o, q, s, u, w, y, za, zc, ze, zg, zi, zk, zm, zo, zq, zs, and zu) or with the anti-E-cadherin antibody (to show the epithelial components of the tissues; b, d, f, h, j, l, n, p, r, t, v, x, z, zb, zd, zf, zh, zj, zl, zn, zp, zr, zt, and zv). zi to zl, mild cervical dysplasia; zm to zp, moderate cervical dysplasia; zq and zr, severe cervical dysplasia. a to d, o to r, and zi to zr, obtained from women ages 35 to 47; e, f, w to zb, zg, zh, and zs to zt, obtained from women ages 55 to 67. In sections containing normal endometrial glands plus endometrial cancer (k-n), the anti-P2X 7 antibody stained the normal glands (k, four glands in the middle; m, two glands at the left bottom corner ) but not the cancerous tissues. y, arrowhead, endocervical columnar (upward) -squamometaplastic (downward) junction. za, arrowhead, squamometaplastic (upward) -squamous (downward) junction. ze and zf, hyperkeratosis. The experiments were repeated two to four times with similar trends. Magnification, Â4 to Â20.
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Cancer Epidemiol Biomarkers Prev 2006;15(10). October 2006 Figure 3 . Expression of the P2X 7 mRNA: in situ hybridization. a to c, cultures of normal human foreskin keratinocytes were either not hybridized (a), hybridized with the sense P2X 7 probe (b), or hybridized with the antisense P2X 7 probe (c). Nuclei were counterstained as described in Materials and Methods. Specific hybridization of the P2X 7 probe in c is seen as intense blue perinuclear and cytoplasmic reaction with the anti-digoxigenin antibody. The experiment was repeated twice with similar trends. d to k, tetracycline repressor -expressing MadinDarby canine kidney cells (MDCK) were transfected with either the P2X 7 cDNA or the P2X 7-j cDNA, grown in the absence (DoxÀ) or presence (Dox+) of doxycyline, and hybridized either with the sense P2X 7 probe (S) or with the antisense P2X 7 probe (AS). Nuclei were not stained. g, specific hybridization of the P2X 7 probe was seen only in doxycyline-treated cells transfected with the P2X 7 cDNA and hybridized with the antisense P2X 7 probe. The experiment was repeated twice with similar trends. l to x, in situ hybridization with the antisense P2X 7 probe of cross-sections of human endometrial (l-o), endocervical (p-s), and ectocervical (t, u, w, and x) tissues. l, m, p, q, and t to v, normal tissues; n, o, r, s, w, and x, cancer tissues. Magnification, Â4 (l, n, p, r, t, v, and w) or Â20 (m, o, q, s, u, and x). v, cross-section of the normal ectocervix hybridized with the sense P2X 7 probe. l, m, p, q, t, and u, specific hybridization of the antisense P2X 7 probe was seen in the epithelia of the normal tissues. The experiment was repeated three to five times with similar trends.
the ectocervix (Fig. 3, t and u) . The subepithelial regions of these tissues stained significantly less.
In cross-sections of the corresponding cancers, no P2X 7 mRNA staining was found (Fig. 3, n, o, r, s, w, and x) . These results confirm the data in Fig. 1C that epithelial uterine cancer cells express minimal amounts of the full-length P2X 7 mRNA.
Quantification of P2X 7 Expression in Normal and Cancer Uterine Tissues. The data in Figs. 1-3 indicate that uterine epithelial cancer cells, in contrast to normal uterine epithelial cells, express low amounts of the full-length P2X 7 mRNA and protein. These data were the basis for the semiquantitative analysis shown in Fig. 4 of full-length P2X 7 mRNA levels (top) and protein levels (bottom) in normal (white columns) and cancer uterine tissues (black columns). P2X 7 mRNA expression was determined in terms of P2X 7 mRNA quantitative PCR levels normalized in each tissue to the constitutive glyceraldehyde-3-phosphate dehydrogenase (e.g., Fig. 1C ). P2X 7 protein levels were determined in terms of densitometry of the P2X 7 65 to 85 -kDa band in Western blots normalized in each tissue to the constitutive tubulin (e.g., Fig. 1A) . Included in the analysis for P2X 7 mRNA were a total of 50 tissues from 36 women, and in the analysis for P2X 7 protein a total of 54 tissues from 41 women. The data in Fig. 4 show that P2X 7 mRNA and protein levels were higher in normal endometrial endocervical and ectocervical tissues than in endometrial, endocervical, and ectocervical cancers. In all cases where normal and cancer tissues were obtained from the same woman, P2X 7 mRNA and protein levels were higher in the normal than in the cancer tissues (Fig. 4) . Figure 5 shows the combined data of Fig. 4 , grouped into P2X 7 mRNA and protein results. Cutoff levels of P2X 7 mRNA and protein were defined as those separating normal (''positive''; empty circles) from cancer tissues (''negative''; filled circles). The cutoff values (in arbitrary units) were established from Fig. 5 as P2X 7 mRNA z1,000 and P2X 7 protein z15. The data of the ''positive'' and ''negative'' P2X 7 mRNA and protein levels grouped by these categories were evaluated using m 2 analysis (Table 1A and B). The results indicate that, for the sample studied in Fig. 4 , the variables of P2X 7 mRNA and P2X 7 protein were sensitive (92%, 100%) and specific (100%, 90%) in differentiating normal and cancer uterine tissues.
The results in Fig. 4 were not affected by the age, race, and ethnic origin of the woman or by the type, stage, or grade of the cancer (data not shown).
Discussion
We found higher levels of expression of P2X 7 mRNA and protein in human uterine epithelial normal tissues than in cancer tissues. The mRNA quantitative PCR and in situ hybridization data as well as the protein Western blot results were specific for the full-length P2X 7 , whereas the immunostaining results most probably represent P2X 7 plus P2X 7-j data. In view of the similar results using the four different end points, it is suggested that the immunostaining results also reflect contributions made primarily by the full-length P2X 7 . The greater expression of P2X 7 in normal versus cancer tissues was not affected by women's age, suggesting that menopause and estrogen status did not significantly affect the expression of the P2X 7 in uterine epithelial cells. It was previously shown that estrogens do exert antiapoptotic effects in the uterus by blocking P2X 7 -mediated apoptosis (7). However, those effects were unrelated to the expression of the P2X 7 receptor and involved modulation of events distal to the receptor (7).
In the normal uterus, most of the full-length P2X 7 was expressed in the epithelial tissues of the endometrium, endocervix, and ectocervix. In the ectocervix, P2X 7 staining was found mainly in cells of the germinative layers. Some staining was also found in superficial layers of the ectocervix, but it probably represents receptor trapped in the flat superficial cells or in the anucleated squames (envelops; ref. 18) . The abundance of expression in the epithelial components of the uterus and particularly in the germinative layers of the ectocervix is in accordance with the presumed role of the P2X 7 as cell growth regulator (7) . Epithelial tissues of the uterus, similar to other surface epithelia, are continuously exposed to stimuli that could alter cell growth. In addition, uterine epithelial cells are also exposed to seminal fluid and sperm cells, and endometrial tissues are exposed to the migrating and implanting blastocyst. The abundance of P2X 7 receptor in the epithelial tissues could be a phylogenetic mechanism to control cell growth of uterine epithelial tissues through apoptosis (4, 11) and to allow sperm Figure 4 . Case-based analysis of tissue expression of P2X 7 mRNA (top) and P2X 7 protein (bottom). Endometrial, endocervical, and ectocervical tissues were obtained from the women identified with the designated codes. In some cases, normal (white columns) and cancer (black columns ) tissues were obtained from the same woman. P2X 7 mRNA levels in each tissue were normalized to glyceraldehyde-3 -p h o s p h a t e d e h y d r o g e n a s e (GAPDH) mRNA (determined by real-time PCR), and P2X 7 protein levels were normalized to tubulin protein levels (determined by densitometry of the 65-85 -kDa complex of the Western blots). AU, arbitrary units. migration through the uterine canal and implantation of the blastocyst in the endometrium without undue mitogenic reaction of the maternal epithelial compartment.
The comparative experiments of the present study focused on common epithelial uterine cancers, which compose >95% of total uterine cancers (19). Because the results were similar regardless of tumor type, adenocarcinomas, and squamous cell carcinomas, it is possible that the differences in the expression of P2X 7 in normal versus cancer tissues are not limited to uterine tissues and that similar effects occur also in other types of epithelial neoplasia. Unpublished preliminary experiments from our laboratory support this statement and have shown similar trends in skin, breast, and prostate tissues.
The differences in the expression of P2X 7 in normal versus cancer tissues are interesting in view of the known compartmentalization of the receptor. The functional P2X 7 receptor resides in the plasma membrane, whereas cytoplasmic staining reflects newly synthesized receptor in transit to the membrane, unprocessed receptor, or postactivation internalized receptor (14) . One of the mechanisms by which cells regulate P2X 7 activity is by modulating membrane expression of the receptor (4). However, the amount of receptor present in the membrane is relatively small (4, 14) , and a more likely explanation for the present results is regulation of P2X 7 activity through the regulation of P2X 7 mRNA levels and protein translation. This conclusion is supported by the P2X 7-j data. mRNA and protein levels of the truncated P2X 7-j were similar in normal and cancer cells; in contrast, mRNA and protein levels of the fulllength P2X 7 were higher in normal versus cancer cells. Because both P2X 7 and P2X 7-j isoforms share a similar promoter (9, 20) , differences in transcription rates are unlikely to explain the findings. An alternative explanation is enhanced degradation of the P2X 7 mRNA in cancer cells or greater stability of the P2X 7 mRNA in the normal cells (21) .
These speculations raise the possibility that uterine cancer cells have developed mechanisms to escape growth control by down-regulation of P2X 7 mRNA. Whether the effect precedes the transformation process (i.e., it is associated with or causes cancer development) or whether it occurs as a result of the neoplastic process is at present unknown. However, regardless of which hypothesis prevails, the present results show that loss of the P2X 7 occurs early on in the neoplastic process because P2X 7 mRNA and protein were absent already in mild cervical dysplasia (Fig. 2, zi and zj) . Therefore, better understanding of the biology and oncology of the P2X 7 receptor may contribute to our understanding of uterine cancer development and progression.
The present results suggest that cellular levels of the fulllength P2X 7 can be used as a novel biomarker to differentiate normal and cancer uterine epithelial tissues. The biochemical assays using minced tissues to determine P2X 7 mRNA and/or protein levels used blocks of tissues that were processed without preseparation of the epithelial components. In the cancer tissue blocks, most of the tissue mass contained cancerous elements; however, in the normal tissue blocks, the epithelial components (endometrium, endocervix, or ectocervix) comprised only small part of the tissues and the remaining mass contained subepithelial stromal components. Because the latter does not contain significant amounts of the P2X 7 ( Fig. 2) and because the results were normalized to tissue total glyceraldehyde-3-phosphate dehydrogenase (for P2X 7 mRNA) and tissue total tubulin (for P2X 7 protein), the determinations in Fig. 4 may have underestimated the P2X 7 mRNA and protein determinations in normal tissues. Accordingly, assays that will aim at collecting samples of surface epithelia may provide more accurate results by retrieving lower amounts of stromal elements. Therefore, the P2X 7 marker could potentially provide a robust method for screening/detection of uterine cancers. An additional potential advantage of using the P2X 7 as a biomarker could be to differentiate cervical dysplasia lesions. The data shown in Fig. 3 (zi-zp) suggest that specimens obtained from mild-moderate dysplasia would yield positive values for P2X 7 mRNA and protein levels (contributed by the normal component of the ectocervical epithelium), whereas severe dysplasia and cancers would be negative. Therefore, theoretically, the P2X 7 method could differentiate between mild/moderate and severe dysplasia. Such a distinction may be of value because this cutoff is often used clinically in the decision-making process of conservative versus surgical management (22) of these cases.
In summary, the present results indicate that levels of the full-length P2X 7 are lower in uterine epithelial cancer tissues than in the corresponding normal tissues. The data suggest that tissue analysis of P2X 7 mRNA and protein levels could be used as a novel biomarker to differentiate normal and cancer uterine epithelial tissues. Future prospective blinded studies are being planned and may be able to determine the usefulness of this biomarker in the clinical setting.
